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Abstract 
Purpose We and others have reported that Sarcophagine-based bifunctional chelators could 
be  effectively  used  in  the  syntheses  of 
64Cu  radiopharmaceuticals.  The  resulted 
64Cu-Sarcophagine complexes demonstrated great in vivo stability. The goal of this study was 
to further derivatize Sarcophagine cage with amino and maleimide functional groups for 
conjugation with bioligands.  
Methods Starting from DiAmSar, three novel chelators (AnAnSar, BaMalSar, and Mal2Sar) with 
two functional groups have been synthesized. Among those, BaMalSar and Mal2Sar have been 
conjugated with cyclic peptide c(RGDyC) (denoted as RGD) and the resulted conjugates, 
BaMalSar-RGD and Mal2Sar-RGD2 have been labeled with 
64Cu. The tumor targeting efficacy 
of 
64Cu-labeled RGD peptides were evaluated in a subcutaneous U87MG glioblastoma xen-
ograft model. 
Results The conjugates, BaMalSar-RGD and Mal2Sar-RGD2 could be labeled with 
64CuCl2 in 10 
min with high purity (>98%) and high radiochemical yield (>90%). Both 
64Cu-BaMalSar-RGD 
and 
64Cu-Mal2Sar-RGD2 exhibited high tumor uptake and tumor-to-normal tissue ratios.  
Conclusion Three novel chelators with two functional groups have been developed based on 
Sarcophagine cage. The platform developed in this study could have broad applications in the 
design and synthesis of
 64Cu-radiopharmaceuticals. 
Key words: Sarcophagine, 64Cu, microPET, RGD, Integrin αvβ3 
Introduction 
The physical characteristics of 64Cu (t1/2 = 12.7 h; 
β+, 0.653MeV [17.8 %]; βˉ, 0.579MeV [38.4 %]) make it 
a  very  important  isotope  in  positron  emission  to-
mography  (PET)  imaging,  especially  for  evaluating 
bioligands with long circulating half lives (> 1 day). In 
addition,  the  advanced  coordination  chemistry  of 
copper has led to a wide variety of efficient chelators 
that could be linked to antibodies, proteins, peptides, 
and  other  biologically  active  molecules  for 
64Cu-radiopharmaceutical synthesis. Among all these 
chelators,  1,4,7,10-tetra-azacyclododecane-N,N',N'', 
N'''-tetraacetic  acid  (DOTA)  is  probably  one  of  the 
most widely used chelators for  64Cu labeling. How-
ever, its moderate in vivo stability could increase the 
Ivyspring  
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non-targeted  organ  radiation  dosage  and  lower  the 
tumor-to-nontumor  contrast  [1-2].  64Cu-Labeled 
radiopharmaceuticals  with  improved  stability  have 
been  reported  including  1,4,7-triazacyclononane- 
1,4,7-triacetic  acid  (NOTA)  derivatives  [3-4], 
cross-bridged  1,4,8,11-tetraazacyclotetradecane-1,4,8, 
11-tetraacetic  acid  (CB-TETA)  [1,  5],  and 
1,4,8,11-tetraazabicyclo[6.6.2]hexadecane  (CB-TE2A) 
[6-8].  For  these  bifunctional  chelators  (BFCs), 
relatively  harsh  conditions,  such  as  elevated 
temperature, may be required for 64Cu chelation. 
The bicyclic chelator, sarcophagine (denoted as 
“Sar”), is well known for its strong binding of Cu(II) 
and  therefore  high  stability  of  its  complexes  [9-11]. 
Based  on  this  cage-like  hexaazamacrobicyclic  sar-
cophagine, a new class of bifunctional chelators has 
been  synthesized  recently.  The  resulting  64Cu 
complexes  demonstrated  great  in  vivo  stability  and 
high  radiolabeling  efficiency  under  mild  conditions 
[12-16].  By  modifying  the  inert  primary  amines  of 
sarcophagine  with  carboxyl  groups,  we  have 
successfully  developed  AmBaSar  and  BaBaSar 
chelators  in  our laboratory [12-14, 17-18]. Biological 
conjugation is generally achieved through three types 
of  functional  groups  on  biomarkers:  amino  group, 
carboxyl group, and sulfhydryl group. Correspond-
ingly,  carboxyl  group,  amino  group,  or  maleimide 
group are expected to be installed onto the chelators 
for bioconjugation. To further explore the scope of the 
applications of Sar chelators, herein we reported the 
syntheses of three new chelators from the Sar cages: 
AnAnSar, BaMalSar, and Mal2Sar. AnAnSar, having 
two reactive amino groups on both sides of the Sar 
cage  could  be  coupled  with  the  carboxyls  of  bi-
omarkers  by  amide  bond  formation.  BaMalSar  and 
Mal2Sar  are  maleimide-containing  Sar  chelators, 
which are designed for biomarkers with free sulfhy-
dryl groups. In order to evaluate the BaMalSar and 
Mal2Sar in vivo performance, we constructed two in-
tegrin  αvβ3-specific  probes:  BaMalSar-RGD  and 
Mal2Sar-RGD2,  and  evaluated  their  tumor  targeting 
efficacy  in  U87MG  tumor  bearing  mice  using  mi-
croPET. 
Materials and methods  
All  chemicals  obtained  commercially  were  of 
analytic grade and used without further purification. 
The  syringe  filter  and  polyethersulfone  membranes 
(pore size, 0.22 μm; diameter, 13 mm) were obtained 
from Nalge Nunc International (Rochester, NY). The 
c(RGDyC)  peptide  were  purchased  from  Peptides 
International (Louisville, KY). A typical linear gradi-
ent HPLC was used for purification and quality con-
trol as following. The reversed-phase HPLC using a 
Vydac protein and peptide column (218TP510; 5µm, 
250 × 4.6 mm) was performed on a Dionex 680 chro-
matography  system  with  a  UVD  170U  absorbance 
detector  (Sunnyvale,  CA)  and  model  105S  sin-
gle-channel  radiation  detector  (Carroll  &  Ramsey 
Associates). At a flow rate of 1 mL/min, the mobile 
phase  was  maintained  at  95%  solvent  A  [0.1%  tri-
fluoroacetic acid (TFA) in water] and 5% B [0.1% TFA 
in  acetonitrile  (MeCN)]  from  0–2  min  and  was 
changed to 35% solvent A and 65% solvent B through 
2–32 min. The UV absorbance was monitored at 218 
nm  and  the  identification  of  the  peptides  was  con-
firmed based on the UV spectrum using a PDA de-
tector. 
Preparation of AnAnSar, BaMalSar, and 
Mal2Sar 
DiAmSar  was  synthesized  as  reported  [12]. 
tert-Butyl  (4-(bromomethyl)phenyl)carbamate  (24.0 
mg, 84.2 µmol) and sodium carbonate (17.0 mg, 160 
µmol) was added to the solution of DiAmSar (20 mg, 
63.7  µmol)  in  N,N-dimethylformamide  (DMF).  The 
reaction was incubated at 70 °C for 12 h. After cooling 
down to room temperature, 1 mL trifluoroacetic acid 
was added to the crude mixture and the reaction was 
maintained  at  room  temperature  for  30  min.  Semi-
preparative HPLC afforded the AnAnSar as slightly 
yellow  solid  (31%,  10.3  mg).  The  retention  time  of 
AnAnSar on analytical HPLC is 6.5 min. Electrospray 
Ionization  Mass  Spectrum  (ESI-MS):  m/z  525.4  for 
[M+H]+  (Chemical  formula:  C28H49N10,  calculated 
m/z value: 525.4). 
The compound BaBaSar was synthesized using 
optimized  method.  In  brief,  methyl 
4-(bromomethyl)benzoate  (21.9  mg,  95.6  µmol)  and 
sodium carbonate (17.0 mg, 160 µmol) were added to 
the solution of DiAmSar (20 mg, 63.7 µmol) in 1:1 tet-
rahydrofuran and methanol. The reaction was incu-
bated at 70 °C for 8 h. After cooling down to room 
temperature,  1  mL  1  N  sodium  hydroxide  (NaOH) 
was  added  to  the  mixture  and  the  reaction  was 
maintained at 60 °C for 2 h. Semipreparative HPLC 
afforded  the  BaBaSar  as  slightly  yellow  solid  (44%, 
16.3 mg). The retention time of BaBaSar on analytical 
HPLC is 8.7 min. Electrospray Ionization Mass Spec-
trum  (ESI-MS):  m/z  583.4  for  [M+H]+  (Chemical 
formula:  C30H47N8O4,  calculated  m/z  value:  583.4). 
HPLC coinjection with BaBaSar standard further con-
firmed the identity of the product [18]. 
To the solution of BaBaSar (2.9 mg, 5µmol) was 
added  1-ethyl-3-(3-dimethylaminopropyl)- 
carbodiimide,  hydrochloric  acid  (EDC)  (1.5  mg,  8 
µmol)  and  N-hydroxysulfosuccinimide  (SNHS)  (1.5 
mg, 7 µmol). After the mixture was adjusted to pH Theranostics 2012, 2(6) 
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5.5–6.0  using  0.1  N  NaOH,  the  reaction  was  main-
tained  at  room  temperature  for  1  h.  Then, 
N-(2-aminoethyl)maleimide  trifluoroacetate  salt  (1.7 
mg, 6.5 µmol) in 500 µL borate buffer (pH 8.5) was 
added to the BaBaSar solution. The reaction stayed at 
4  °C  overnight.  HPLC  purification  afforded  the 
product BaMalSar (1.3 mg, 37%) and Mal2Sar (1.0 mg, 
25%) as white powder. The retention time of BaMal-
Sar on analytical HPLC is 14.1 min. Electrospray Ion-
ization  Mass  Spectrum  (ESI-MS):  m/z  705.4  for 
[M+H]+  (Chemical  formula:  C36H53N10O5,  calculated 
m/z value: 705.4). The retention time of Mal2Sar on 
analytical HPLC is 14.9 min. Electrospray Ionization 
Mass  Spectrum  (ESI-MS):  m/z  827.5  for  [M+H]+ 
(Chemical formula: C42H59N12O6, calculated m/z val-
ue: 827.5). 
Preparation of BaMalSar-RGD and 
Mal2Sar-RGD2 
To  BaMalSar  (2.4  mg,  3.4  µmol)  in  phosphate 
buffer (pH 6.5–7.0) was added c(RGDyC) (1.8 mg, 3.0 
µmol). The reaction stayed at room temperature for 10 
min  and  HPLC  afforded  BaMalSar-RGD  as  white 
powder  (yield  92%,  3.6  mg).  The  retention  time  of 
BaMalSar-RGD  on  analytical  HPLC  is  15.5  min. 
ESI-MS: m/z 1299.7 for [M+H]+ (Chemical formula: 
C60H87N18O13S,  calculated  m/z  value:  1299.6).  To 
Mal2Sar (2.8 mg, 3.4 µmol) in phosphate buffer (pH 
6.5–7.0) was added c(RGDyC) (5.2 mg, 8.8 µmol). The 
reaction  stayed  at  room  temperature  for  2  h  and 
HPLC afforded Mal2Sar-RGD2 as white powder (yield 
85%, 5.8 mg). The retention time of Mal2Sar-RGD2 on 
analytical HPLC is 14.6 min. ESI-MS: m/z 1008.5 for 
[M+2H]2+ (Chemical formula: C90H128N28O22S2, calcu-
lated m/z2+ value: 1008.5). 
Radiochemistry 
The  labeling  was  performed  similar  to  the  re-
ported procedure [18]. In brief, 20 µL 64CuCl2 (74 MBq, 
2.0 mCi in 0.1 N HCl) was diluted in 200 µL of 0.1 N 
ammonium acetate (NH4OAc, pH 5.5) and added to 
BaMalSar-RGD  or  Mal2Sar-RGD2  (5–10  µg  per  mCi 
64Cu). The reaction mixture was kept at 37 °C for 10 
min. 64Cu-labeled peptide was subsequently purified 
by  analytical  HPLC  and  the  radioactive  peak  con-
taining the desired product was collected. After re-
moval of the solvent by rotary evaporation, the con-
jugated  peptide  tracer  was  reconstituted  in  1  mL 
phosphate buffer saline (PBS) and passed through a 
0.22 µm syringe filter for in vivo animal experiments. 
The  decay-corrected  radiochemical  yield  (RCY)  for 
64Cu-BaMalSar-RGD  and  64Cu-Mal2Sar-RGD2  was 
95% and 92% respectively. 
Cell Culture 
Human glioblastoma cell line U87MG was ob-
tained  from  the  American  Type  Culture  Collection 
(Manassas,  VA)  and  were  cultured  in  DMEM  con-
taining high glucose (GIBCO, Carlsbad, CA), which 
was supplemented with 10% fetal bovine serum (FBS) 
and  1%  penicillin-streptomycin.  The  cells  were  ex-
panded in tissue culture dishes and kept in a humidi-
fied atmosphere of 5% CO2 at 37 °C. The medium was 
changed every other day. A confluent monolayer was 
detached with 0.05% Trypsin-EDTA, 0.01M PBS (pH 
7.4) and dissociated into a single-cell suspension for 
further cell culture.  
MicroPET Imaging 
Animal procedures were performed according to 
a  protocol  approved  by  the  University  of  Southern 
California  Institutional  Animal  Care  and  Use  Com-
mittee.  MicroPET  scans  were  performed  on  a  mi-
croPET  R4  rodent  model  scanner  (Siemens  Medical 
Solutions USA, Inc., Knoxville, TN). The scanner has a 
computer-controlled bed and 10.8-cm transaxial and 
8-cm axial fields of view (FOVs). It has no septa and 
operates  exclusively  in  the  3-dimensional  (3D)  list 
mode.  Animals  were  placed  near  the  center  of  the 
FOV  of  the  scanner.  For  static  microPET  scans,  the 
mice bearing U87MG xenografts were injected with 
about  3.7  MBq  (100  μCi)  of  64Cu-BaMalSar-RGD  or 
64Cu-Mal2Sar-RGD2 via the tail vein (n = 3 for each 
group). Similarly, the blocking study was performed 
by  injecting  the  probe  with  c(RGDyC)  (10  mg/kg 
body weight) through the tail vein (n = 3). At 1 h, 4 h, 
and 20 h post injection (p.i.), the mice were anesthe-
tized  with  isoflurane  (5%  for  induction  and  2%  for 
maintenance  in  100%  O2)  using  a  knock-down  box. 
With the help of a laser beam attached to the scanner, 
the mice were placed in the prone position and near 
the  center  of  the  field  of  view  of  the  scanner.  The 
3-min static scans were then obtained. Images were 
reconstructed  by  use  of  a  2-dimensional  or-
dered-subsets  expectation  maximization  (OSEM)  al-
gorithm. No background correction was performed. 
Regions  of  interest  (ROIs;  5  pixels  for  coronal  and 
transaxial slices) were drawn over the tumor on de-
cay-corrected whole-body coronal images. The max-
imum  counts  per  pixel  per  minute  were  obtained 
from the ROI and converted to counts per milliliter 
per minute by using a calibration constant. With the 
assumption of a tissue density of 1 g/ml, the ROIs 
were converted to counts per gram per min. Image 
ROI-derived  %ID/g  values  were  determined  by  di-
viding counts per gram per minute by injected dose. 
No attenuation correction was performed. Theranostics 2012, 2(6) 
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Statistical Analysis 
Quantitative data are expressed as mean ± SD. 
Means were compared using 1-way ANOVA and the 
Student t test. P values of < 0.05 were considered sta-
tistically significant. 
Results  
Chemistry and Radiochemistry 
The  chelator  An(Boc)An(Boc)Sar  was  prepared 
by  direct  alkylation  of  DiAmSar  using  tert-butyl 
(4-(bromomethyl)phenyl)carbamate  (Fig.  1).  Depro-
tection  with  TFA  afforded  AnAnSar  in  31%  yield. 
BaBaSar was activated with EDC/SNHS, followed by 
the  conjugation  with  N-(2-aminoethyl)maleimide  to 
afford BaMalSar and Mal2Sar (Fig. 1). The yields of 
BaMalSar  and  Mal2Sar  were  37%  and  25%,  respec-
tively. BaMalSar and Mal2Sar were conjugated with 
c(RGDyC) to give BaMalSar-RGD and Mal2Sar-RGD2 
in  92%  and  85%  yields,  respectively  (Fig.  2).  The 
products were purified by HPLC and characterized 
by  ESI-MS.  The  purity  of  each  RGD  conjugate  was 
determined to be > 95% by HPLC. The 64Cu labeling 
procedure was done within 1 h (including the radioi-
sotope  incorporation,  HPLC  purification,  rotary 
evaporation,  and  formulation  in  PBS)  with  a  de-
cay-corrected yield higher than 90% and more than 
98% radiochemical purity. The specific activity of pu-
rified  64Cu-BaMalSar-RGD  and  64Cu-Mal2Sar-RGD2 
were about 200–300 mCi/µmol. 
MicroPET imaging study 
Static  microPET  scans  were  performed  on  a 
U87MG  tumor  model  and  representative  de-
cay-corrected coronal images at 1, 4, and 20 h after tail 
vein  injection  of  64Cu-BaMalSar-RGD  and 
64Cu-Mal2Sar-RGD2  are  shown  in  Fig.  3  (n  =  3  per 
group). The U87MG tumors were clearly visualized 
with  good  tumor-to-background  contrast  for  both 
tracers. The uptake in the tumor or other organs was 
measured from the ROI analysis and shown in Fig. 3. 
For 64Cu-BaMalSar-RGD, the tumor uptake was 3.02 ± 
0.20, 2.55 ± 0.43, and 2.05 ± 0.18 %ID/g, at 1, 4, and 20 
h p.i., respectively. For 64Cu-Mal2Sar-RGD2, the tumor 
uptake was 5.56 ± 0.38, 5.01 ± 0.19, and 3.81 ± 0.14 
%ID/g, at 1, 4, and 20 h p.i., respectively. The tumor 
uptake of 64Cu-Mal2Sar-RGD2 was significantly higher 
than that of 64Cu-BaMalSar-RGD (P < 0.01, Fig. 4) at all 
three time points examined. Both of the tracers cleared 
rapidly  from  the  blood,  and  were  excreted  mainly 
through the kidneys as evidenced by the high kidney 
uptake. The liver uptakes of 64Cu-BaMalSar-RGD and 
64Cu-Mal2Sar-RGD2  were  significantly  lower  than 
tumor and kidneys at all time-points indicating the 
good in vivo stability of the 64Cu chelation indirectly. 
The nonspecific uptake in the muscle and lung was 
very low for both tracers. 
 
Fig.  1  BFC  syntheses.  (a).  tert-butyl 
(4-(bromomethyl)phenyl)carbamate,  DMF, 
Na2CO3, 12 h. (b). TFA, 30 min. (c). EDC, 
SNHS,  pH  5.5,  1h.  (d). 
2-aminoethylmaleimide,  borate  buffer,  pH 
8.5. Theranostics 2012, 2(6) 
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Fig. 2 Structures of c(RGDyC), BaMalSar-RGD, and Mal2Sar-RGD2. 
 
 
 
Fig. 3 Decay-corrected whole-body coronal 
microPET  images  of  athymic  female  nude 
mice  bearing  U87MG  tumor  from  a  static 
scan at 1 h, 4 h, and 20 h after the injection of 
64Cu-BaMalSar-RGD,  and 
64Cu-Mal2Sar-RGD2,  with  or  without 
c(RGDyC) as the blocking agent (10 mg/kg 
body weight). Tumors are indicated by ar-
rows. Theranostics 2012, 2(6) 
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Fig.  4 MicroPET quantification of tumors and major organs at 1 h, 4 h, and 20 h after the injection of  64Cu-BaMalSar-RGD, and 
64Cu-Mal2Sar-RGD2, with or without c(RGDyC) as the blocking agent (10 mg/kg body weight). 
 
The  integrin  αvβ3  targeting  specificities  of 
64Cu-BaMalSar-RGD  and  64Cu-Mal2Sar-RGD2  were 
demonstrated  by  co-injection  of  excess  RGD  as  the 
blocking agent (Fig. 4). Co-injection of excess dose of 
RGD  significantly  lower  the  tumor  uptake  for 
64Cu-BaMalSar-RGD  and  64Cu-Mal2Sar-RGD2.  For 
example,  at  1  h  p.i.,  the  tumor  uptake  of 
64Cu-BaMalSar-RGD with blocking RGD agent is 1.04 
± 0.17 %ID/g (vs. 3.02 ± 0.20 %ID/g without RGD) 
and the tumor uptake of 64Cu-Mal2Sar-RGD2 is 1.10 ± 
0.13 %ID/g with the blocking RGD agent (vs. 5.56 ± 
0.38 %ID/g without RGD) (Fig. 4). 
Discussion  
Although  sarcophagine  64Cu2+  complexes  have 
been demonstrated to be superior to other chelators 
such  as  DOTA  with  respect  to  in vivo  stability,  at-
tempts to attach the DiAmSar directly to protein using 
EDC activation has been unsuccessful due to its rela-
tively inert primary amine [15]. In order to overcome 
this  limitation,  it  is  necessary  to  further  derivatize 
these  hexaazamacrobicyclic  caged-like  BFCs,  which 
would  allow  the  conjugation  of  sarcophagine  with 
bioligands  using  conventional  synthetic  strategies 
such as amide bond formation. For example, mono-
functionalized AmBaSar and SarAr have been devel-
oped  for  64Cu  radiopharmaceuticals  [14,  16, 19].  As 
sarcophagine has two relatively inert primary amines 
on either end of its cage, we have focused on devel-
oping novel Sar cage derivatives with multifunctional 
groups introduced  to both ends.  Recently,  we have 
successfully improved the functionalization approach 
of the Sar cage through a direct alkylation (SN2) reac-
tion  [18].  The  bi-functionalized  BaBaSar  chelator 
demonstrated the superior properties compared with 
the  mono-functionalized  AmBaSar  for  constructing 
64Cu radiopharmaceuticals. Here, we further extended 
our effort and developed three new BFCs with two 
functional  groups  for  the  64Cu  radiopharmaceutical 
synthesis.  
In our first design, we proposed to introduce two 
aromatic amines to the DiAmSar backbone through 
the direct alkylation (SN2) reaction [18]. As expected, 
An(Boc)An(Boc)Sar  was  successfully  synthesized 
through  the  alkylation  between  tert-butyl 
(4-(bromomethyl)phenyl)carbamate  and  DiAmSar. 
After  deprotection,  AnAnSar  was  obtained  in  31% 
isolation yield. At the same time, the monoalkylated 
product, SarAr, was afforded as a side product, which 
could also be useful for bioligands conjugation. Simi-
lar to the bifunctional BaBaSar, the free amino groups 
from AnAnSar should be able to react with the acti-
vated carboxylate groups to construct multivalent or 
multimodality imaging agent. Moreover, the aromatic 
amine could be selectively reacted without interfer-
ence from a crosslink reaction between the activated Theranostics 2012, 2(6) 
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carboxylate group and lysine amines [20]. 
The major concern for protein labeling through 
amide  bond  formation  is  the  possible  interference 
with biological activity; modification of one or more 
lysines or carboxylic acids located at or near the active 
site could reduce the binding affinity. Thiol-reactive 
agents have also been used to modify peptides and 
proteins at specific sites, providing high chemoselec-
tivity as compared with amine or carboxylate-reactive 
reagents [21-22]. Starting from BaBaSar, the thiol re-
active chelators BaMalSar and Mal2Sar were synthe-
sized through a two-step reaction: (1) activation of the 
benzoic  acid  moieties  in  BaBaSar  with  EDC/SNHS; 
(2) installment of maleimide functional group via an 
amide  bond  formation.  During  the  preparation  of 
starting material BaBaSar, it was found that the reac-
tion  yield  could  be  significantly  improved  if  me-
thyl-4-bromomethylbenzoate was used as the alkyla-
tion  agent  for  DiAmSar  (instead  of  using 
4-bromomethylbenzoic  acid).  Although  this  modifi-
cation  did  require  one  extra  deprotection  step,  the 
reaction yield could be as high as 91% based on both 
AmBaSar and BaBaSar. This improved method  was 
used for AmBaSar and BaBaSar synthesis thereafter. 
At this stage, we have developed a library of multi-
functional Sar chelators that could be used for amino, 
carboxyl, and sulfhydryl conjugation with bioligands.  
To demonstrate the application of our Sar che-
lators  in  64Cu  radiopharmaceuticals,  both  BaMalSar 
and  Mal2Sar  were  selected  and  conjugated  with 
c(RGDyC)  [23-25].  The  free  sulfhydryl  group  on 
c(RGDyC) reacted with both chelators in high yield 
under mild condition (neutral pH and room temper-
ature)  to  afford  BaMalSar-RGD  and  Mal2Sar-RGD2. 
This conjugation could be ideal when the bioligands 
are susceptible to acid, base, or high reaction temper-
ature. It also provides an excellent alternative to the 
widely  used  DOTA-NHS.  Furthermore,  this  sulfhy-
dryl-specific reaction could avoid reducing the target 
binding affinity if the lysine or terminal amino groups 
are at or near the active site of a peptide or protein. 
Both  of  the  BaMalSar-RGD  and  Mal2Sar-RGD2 
were  labeled  with  64Cu  very  efficiently  in  0.1  M 
NH4OAc buffer within 10 min in high yield. Although 
the  specific  activity  of  64Cu-BaMalSar-RGD  and 
64Cu-Mal2SarSar-RGD2 was about 200–300 mCi/µmol, 
decreasing the loading of sarcophagine RGD and us-
ing more  64Cu for the labeling will increase the spe-
cific activity some extent. These probes demonstrated 
the high tumor to background ratios. For example, the 
tumor to muscle ratio reached 20.46 ± 4.47 at 4 h post 
injection  of  64Cu-Mal2Sar-RGD2,  which  is  consistent 
with  high  contrast  shown  in  Fig.  3. 
64Cu-Mal2Sar-RGD2  also  had  significantly  increased 
tumor  uptake  compared  with  64Cu-BaMalSar-RGD, 
which could be caused by a multivalency effect as has 
been observed before [8, 26-28]. Similar to previous 
reports,  increased  tumor  uptake  was  accompanied 
with an elevated kidney uptake [27-28]. In the block-
ing study, the tumor uptakes of 64Cu-BaMalSar-RGD 
and  64Cu-Mal2Sar-RGD2  were  reduced  to  the  same 
level (no significant difference,  P > 0.05) after satu-
rating the integrin receptors by large excess of unla-
beled RGD peptide. The residual background uptake 
may  be  related  to  passive  targeting  of  the  probes. 
Nonetheless,  the  efficient  blocking  results  clearly 
demonstrated the receptor specificity of our probes.  
Previously,  64Cu  labeled  DOTA-c(RGDyK)  had 
been tested in U87MG human glioma tumors [29]. The 
observed tumor to muscle ratios were 7.10 ± 1.30, and 
6.30 ± 1.28 at 1, and 4 h post injection. In this study, 
the tumor to muscle ratios reached 11.71 ± 3.58, and 
26.78 ±  15.18  for  64Cu-BaMalSar-RGD  at  1,  and  4  h 
post  injection.  The  improved  in  vivo  kinetics  are 
extremely important for 64Cu based PET imaging and 
therapy.  It  has  been  pointed  out  that  the 
transchelation  of  64Cu  from  DOTA  to  superoxide 
dismutase in the liver and the persistent localization 
of the final radiometal metabolite  64Cu-DOTA lysine 
within the tissue are disadvantageous for 64Cu-DOTA 
therapy  application  [30].  The  demonstrated  high  in 
vivo stability of  64Cu-sarcophagine  [16, 18], plus the 
ease  of  conjugation  reported  herein  (such  as 
maleimido-chelators with free sulfhydryl containing 
biomarkers), will expedite the  64/67Cu application in 
both  imaging  and  therapy  fields.  We  also  need  to 
point out that BaMalSar is a heterofunctional chelator. 
In this proof of principle study, we only modified one 
side  with  c(RGDyC)  using  the  site-specific 
sulfhydryl-maleimide Michael addition. Conjugation 
of a second biomarker on the benzoic acid moiety of 
BaMalSar,  will  allow  us  to  readily  contruct  novel 
multinodality or heterofunctional probes. 
Conclusion 
Three  novel  bifunctional  chelators  for  the 
prepareation of 64Cu radiopharmaceuticals have been 
successfully synthesized. BaMalSar and Mal2Sar were 
conjugated  with  cyclic  c(RGDyC)  through  free 
sulfhydryl and maleimide reactions. The conjugates, 
BaMalSar-RGD  and  Mal2Sar-RGD2  could  be  labeled 
with  64CuCl2, and exhibited high tumor uptake and 
tumor-to-normal  tissue  ratios.  In  the  future,  two 
different  bioligands  will  be  installed  into  the  two 
pedant arms of AnAnSar,  MalBaSar, or Mal2Sar for 
constructing dual targeting probes. Furthermore, the 
two reactive sites of AnAnSar, BaMalSar and Mal2Sar 
could be used to attach a targeting moiety on one side Theranostics 2012, 2(6) 
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and  an  additional  label  (for  secondary  imaging 
modality) on the other. We anticipate that this newly 
developed method will offer a novel way to construct 
multimodality imaging probes as well.  
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